What is Imunon Inc's earnings per share (EPS)?

Imunon Inc (IMNN) reported diluted earnings per share of -$6.83 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Imunon Inc Financials

IMNN

FY2025 annual

Revenue Not reported for FY2025

Net Income $14.5M +177.8% YoY

EPS (Diluted) -$6.83 YoY not available

Free Cash Flow -$14.2M +24.9% YoY

Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2026 Currency USD FYE December

This page shows Imunon Inc (IMNN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI IMNN FY2025 2026-05-12

External financing still underwrites research-driven operations, even as FY2025 showed a smaller but still material cash burn.

Liquidity improved for a reason the income statement does not show: operating cash burn narrowed from $19.0M in FY2024 to $13.9M in FY2025, yet cash still rose to $8.8M only because financing brought in $17.1M. That mix of lower burn and continued dependence on outside capital says the operating model is becoming leaner, not self-funding.

Capital intensity is low: FY2025 capex was only $281K against -$14.2M of free cash flow, so cash use is tied mainly to research activity and overhead, not to replenishing a heavy physical asset base.

Expense structure is concentrated in development spending: R&D of $7.8M plus SG&A of $6.9M almost exactly matched the FY2025 operating loss of $14.7M, which implies the company is still essentially a funded development platform rather than a business where revenue absorbs the fixed-cost shell. Even so, near-term balance-sheet flexibility improved as the current ratio moved to 2.3x from 1.7x and debt-to-equity fell to 0.7x from 1.3x after the financing inflow.

Financial Health Signals

Financial health score not available

Imunon Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

3/6

Imunon Inc passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

$0.96used

For every $1 of reported earnings, Imunon Inc used $0.96 of operating cash (-$13.9M OCF vs $14.5M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$14.4M

YoY+24.0%

Imunon Inc's EBITDA was -$14.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 24.0% from the prior year.

Net Income

$14.5M

YoY+177.8%

Imunon Inc reported $14.5M in net income in fiscal year 2025. This represents an increase of 177.8% from the prior year.

EPS (Diluted)

-$6.83

Imunon Inc earned -$6.83 per diluted share (EPS) in fiscal year 2025.

Revenue

Not reported for fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

-$14.2M

YoY+24.9%

Imunon Inc recorded an outflow of $14.2M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 24.9% from the prior year.

Cash & Debt

$8.8M

YoY+49.5%

5Y CAGR-12.5%

10Y CAGR-0.5%

Imunon Inc held $8.8M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

Imunon Inc had 3M shares outstanding in fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity

205.3%

YoY+644.0pp

5Y CAGR+320.7pp

10Y CAGR+315.4pp

Imunon Inc's ROE was 205.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 644.0 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not reported for fiscal year 2025.

Net Margin

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

$7.8M

YoY-33.2%

5Y CAGR-7.3%

10Y CAGR-6.1%

Imunon Inc invested $7.8M in research and development in fiscal year 2025. This represents a decrease of 33.2% from the prior year.

Capital Expenditures

$281K

YoY+849.8%

5Y CAGR+71.2%

10Y CAGR+9.9%

Imunon Inc invested $281K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 849.8% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

IMNN Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

IMNN annual income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	N/A	N/A	N/A	N/A	$500K0.0%	$500K0.0%	$500K0.0%	$500K0.0%	$500K0.0%	$500K	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$7.8M-33.2%	$11.6M+3.1%	$11.3M-3.8%	$11.7M+10.5%	$10.6M-6.4%	$11.3M-13.2%	$13.1M+10.1%	$11.9M-9.3%	$13.1M-10.6%	$14.6M-0.3%	$14.7M-2.1%	$15.0M+59.9%	$9.4M-40.6%	$15.8M-20.6%	$19.9M
SG&A Expenses	N/A	$6.9M-8.3%	$7.5M-23.1%	$9.7M-28.8%	$13.7M+25.7%	$10.9M+42.5%	$7.6M-4.5%	$8.0M-17.5%	$9.7M+64.7%	$5.9M-9.8%	$6.5M-2.4%	$6.7M-24.5%	$8.9M+35.3%	$6.5M+2.7%	$6.4M+23.6%	$5.2M
Operating Income	N/A	-$14.7M+23.4%	-$19.1M+9.0%	-$21.0M+15.6%	-$24.9M-18.6%	-$21.0M-13.6%	-$18.5M+10.1%	-$20.6M+2.4%	-$21.1M-14.1%	-$18.5M+10.6%	-$20.6M+0.9%	-$20.8M+15.7%	-$24.7M-60.4%	-$15.4M+30.4%	-$22.1M+3.8%	-$23.0M
Interest Expense	N/A	N/A	N/A	$197K-96.1%	$5.0M+782.4%	$570K-55.9%	$1.3M-7.3%	$1.4M+95.7%	$712K+676.0%	$92K-87.3%	$723K-46.7%	$1.4M+2.3%	$1.3M+44.9%	$915K+154.6%	$359K-28.4%	$502K
Income Tax	N/A	N/A	N/A	-$1.3M+18.3%	-$1.6M-13.3%	-$1.4M+25.0%	-$1.8M-1.6%	-$1.8M+82.6%	-$10.4M	N/A	N/A	N/A	N/A	N/A	N/A	$0
Net Income	N/A	$14.5M+177.8%	-$18.6M+4.6%	-$19.5M+45.6%	-$35.9M-72.8%	-$20.8M+3.3%	-$21.5M-27.5%	-$16.9M-41.8%	-$11.9M+41.8%	-$20.4M+7.5%	-$22.1M+1.8%	-$22.5M+11.9%	-$25.5M-209.0%	-$8.3M+68.9%	-$26.6M-14.4%	-$23.2M
EPS (Diluted)	—	-$6.83	-$16.94	-$2.16+57.1%	-$5.03	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
R&D Expenses	$1.5M-37.3%	$2.3M	N/A	$1.9M+54.8%	$1.2M-43.3%	$2.2M	N/A	$3.3M
SG&A Expenses	$1.3M-32.6%	$2.0M	N/A	$1.6M+2.3%	$1.5M-22.2%	$2.0M	N/A	$1.7M
Operating Income	-$2.8M+35.2%	-$4.3M	N/A	-$3.5M-25.6%	-$2.8M+33.2%	-$4.1M	N/A	-$5.0M
Interest Expense	$77K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$2.8M+33.8%	-$4.2M	N/A	-$3.4M-25.1%	-$2.7M+33.2%	-$4.1M	N/A	-$4.8M
EPS (Diluted)	-$0.54+35.7%	-$0.84	N/A	-$1.16	-$2.15	-$3.15	N/A	-$3.76

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

IMNN Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

IMNN annual balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$12.3M+26.5%	$9.7M-55.7%	$21.9M-50.2%	$44.0M-40.6%	$74.0M+97.3%	$37.5M-2.0%	$38.3M-18.3%	$46.9M-1.4%	$47.5M+54.0%	$30.8M-37.1%	$49.0M-26.5%	$66.7M+46.0%	$45.7M+80.1%	$25.4M-22.3%	$32.6M
Current Assets	$10.7M+33.9%	$8.0M-56.1%	$18.2M-50.4%	$36.8M-29.2%	$51.9M+175.9%	$18.8M+16.0%	$16.2M-42.3%	$28.1M+15.7%	$24.3M+438.8%	$4.5M-77.8%	$20.3M-45.9%	$37.5M-14.3%	$43.8M+85.0%	$23.6M-24.9%	$31.5M
Cash & Equivalents	$8.8M+49.5%	$5.9M+0.6%	$5.8M-49.2%	$11.5M-41.3%	$19.6M+14.1%	$17.2M+149.7%	$6.9M-48.5%	$13.4M+16.7%	$11.4M+336.1%	$2.6M-71.7%	$9.3M-27.0%	$12.7M+121.9%	$5.7M-61.9%	$15.0M-25.6%	$20.1M
Accounts Receivable	$0	$0	$0	$0	N/A	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	$2.0M0.0%	$2.0M0.0%	$2.0M0.0%	$2.0M0.0%	$2.0M0.0%	$2.0M0.0%	$2.0M	N/A	N/A	N/A
Total Liabilities	$5.2M-4.5%	$5.5M-35.8%	$8.5M-41.8%	$14.6M-19.7%	$18.3M-3.5%	$18.9M-20.2%	$23.7M-8.8%	$26.0M+24.9%	$20.8M-13.7%	$24.1M-15.8%	$28.6M-15.4%	$33.9M+139.4%	$14.1M+5.6%	$13.4M+107.5%	$6.5M
Current Liabilities	$4.6M-3.4%	$4.8M-35.2%	$7.4M-26.4%	$10.0M+48.3%	$6.8M+0.2%	$6.8M-14.5%	$7.9M+29.3%	$6.1M-1.5%	$6.2M-26.4%	$8.4M-9.7%	$9.3M-7.6%	$10.1M+116.0%	$4.7M-6.7%	$5.0M-18.6%	$6.2M
Long-Term Debt	N/A	N/A	N/A	$6.0M	N/A	$5.1M-48.5%	$9.8M+4.1%	$9.4M	N/A	N/A	N/A	N/A	$5.0M0.0%	$5.0M	N/A
Total Equity	$7.1M+66.4%	$4.2M-68.3%	$13.4M-54.4%	$29.3M-47.4%	$55.8M+199.8%	$18.6M+27.8%	$14.6M-30.2%	$20.9M-21.9%	$26.7M+297.0%	$6.7M-67.0%	$20.4M-37.9%	$32.8M+4.1%	$31.5M+163.5%	$12.0M-54.3%	$26.2M
Retained Earnings	-$421.3M-3.6%	-$406.8M-4.8%	-$388.2M-5.3%	-$368.7M-10.8%	-$332.8M-6.7%	-$312.0M-7.4%	-$290.5M-6.2%	-$273.7M-4.5%	-$261.8M-8.5%	-$241.4M-10.7%	-$218.1M-11.8%	-$195.1M-15.2%	-$169.3M-8.3%	-$156.3M-25.8%	-$124.2M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$15.0M+86.9%	$8.0M-34.7%	$12.3M+36.7%	$9.0M+2.3%	$8.8M+28.1%	$6.9M-29.4%	$9.7M-32.5%	$14.4M
Current Assets	$8.7M+31.3%	$6.6M-38.3%	$10.7M+47.8%	$7.3M+5.3%	$6.9M+35.3%	$5.1M-36.4%	$8.0M-36.1%	$12.5M
Cash & Equivalents	$6.9M+43.2%	$4.8M-45.4%	$8.8M+67.2%	$5.3M+11.0%	$4.7M+64.7%	$2.9M-51.1%	$5.9M-43.0%	$10.3M
Accounts Receivable	N/A	N/A	$0	N/A	N/A	N/A	$0	N/A
Total Liabilities	$10.8M+131.8%	$4.7M-10.9%	$5.2M+6.5%	$4.9M-19.9%	$6.1M-4.4%	$6.4M+17.1%	$5.5M-11.7%	$6.2M
Current Liabilities	$4.8M+14.7%	$4.2M-9.9%	$4.6M+10.1%	$4.2M-21.1%	$5.3M-8.3%	$5.8M+21.1%	$4.8M-12.0%	$5.4M
Total Equity	$4.2M+24.7%	$3.4M-52.4%	$7.1M+73.0%	$4.1M+53.5%	$2.7M+488.4%	$452K-89.3%	$4.2M-48.2%	$8.2M
Retained Earnings	-$428.4M-0.7%	-$425.5M-1.0%	-$421.3M-1.0%	-$417.1M-0.8%	-$413.6M-0.7%	-$410.9M-1.0%	-$406.8M-1.0%	-$402.7M

Not reported in any period shown, so not listed: Inventory.

IMNN Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

IMNN annual cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	-$15.1M	-$13.9M+26.3%	-$18.9M+0.9%	-$19.0M+17.6%	-$23.1M-42.4%	-$16.2M-3.9%	-$15.6M+22.9%	-$20.3M-187.7%	-$7.0M+57.7%	-$16.6M+9.5%	-$18.4M+11.8%	-$20.8M+2.4%	-$21.4M-124.2%	-$9.5M+57.0%	-$22.1M+2.6%	-$22.7M
Capital Expenditures	N/A	$281K+849.8%	$30K-93.5%	$452K+68.7%	$268K-14.1%	$312K+1532.2%	$19K-94.5%	$349K+152.3%	$138K+258.3%	$39K-38.2%	$63K-42.8%	$109K-83.7%	$672K+1069.3%	$57K-90.6%	$613K+7.0%	$573K
Free Cash Flow	N/A	-$14.2M+24.9%	-$18.9M+3.0%	-$19.5M+16.7%	-$23.4M-41.3%	-$16.5M-5.7%	-$15.6M+24.1%	-$20.6M-187.0%	-$7.2M+57.0%	-$16.7M+9.5%	-$18.4M+11.9%	-$20.9M+4.9%	-$22.0M-129.8%	-$9.6M+57.9%	-$22.8M+2.4%	-$23.3M
Investing Cash Flow	N/A	-$281K-102.9%	$9.8M-10.7%	$11.0M+32.9%	$8.3M+127.5%	-$30.1M-480.1%	$7.9M+33.5%	$5.9M+463.6%	-$1.6M+85.2%	-$11.0M-221.3%	$9.1M-32.0%	$13.3M+39.6%	$9.5M+132.8%	-$29.1M-2080.9%	$1.5M+113.3%	-$11.1M
Financing Cash Flow	$22.3M	$17.1M+88.6%	$9.1M+349.0%	-$3.6M-154.1%	$6.7M-87.7%	$54.8M+204.5%	$18.0M+129.2%	$7.8M-25.9%	$10.6M-71.0%	$36.5M+1261.4%	$2.7M-34.4%	$4.1M-78.3%	$18.8M-36.1%	$29.4M+89.4%	$15.5M-70.6%	$52.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$346K	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$3.0M+24.1%	-$4.0M-9.0%	-$3.7M+17.7%	-$4.4M-50.5%	-$3.0M-3.7%	-$2.8M+35.6%	-$4.4M-9.0%	-$4.1M
Capital Expenditures	N/A	N/A	$4K	$0-100.0%	$17K-93.3%	$260K+1641.8%	$15K+417.8%	$3K
Free Cash Flow	N/A	N/A	-$3.7M+17.6%	-$4.4M-49.6%	-$3.0M+4.4%	-$3.1M+30.0%	-$4.4M-9.3%	-$4.1M
Investing Cash Flow	N/A	N/A	-$4K	$0+100.0%	-$17K+93.3%	-$260K-1641.8%	-$15K-417.8%	-$3K
Financing Cash Flow	$10.2M+560764.3%	-$2K-100.0%	$7.2M+44.9%	$5.0M+2.8%	$4.8M+4465.9%	$106K+3325.3%	-$3K	N/A

Not reported in any period shown, so not listed: Share Buybacks.

IMNN Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

IMNN annual financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Margin	N/A	N/A	N/A	-4984.3%	-4201.4%	-3697.3%	-4113.1%	-4213.0%	-3693.7%	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	-7179.6%	-4153.9%	-4296.7%	-3370.3%	-2376.7%	-4080.4%	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	205.3%+644.0pp	-438.7%-292.9pp	-145.8%-23.4pp	-122.4%-85.2pp	-37.2%+78.2pp	-115.4%+0.3pp	-115.8%-58.8pp	-57.0%+19.4pp	-76.4%+251.5pp	-327.9%-217.7pp	-110.2%-32.5pp	-77.7%-51.5pp	-26.2%+195.9pp	-222.1%-133.4pp	-88.7%
Return on Assets	118.0%+309.6pp	-191.6%-102.6pp	-89.0%-7.4pp	-81.6%-53.6pp	-28.1%+29.2pp	-57.3%-13.2pp	-44.0%-18.7pp	-25.4%+17.6pp	-42.9%+28.5pp	-71.5%-25.7pp	-45.8%-7.6pp	-38.2%-20.2pp	-18.1%+86.7pp	-104.8%-33.6pp	-71.1%
Current Ratio	2.32+0.6x	1.67-0.8x	2.47-1.2x	3.66-4.0x	7.67+4.9x	2.79+0.7x	2.06-2.6x	4.61+0.7x	3.92+3.4x	0.54-1.6x	2.18-1.5x	3.72-5.7x	9.37+4.6x	4.72-0.4x	5.12
Debt-to-Equity	0.74-0.5x	1.29+0.7x	0.64+0.4x	0.20-0.1x	0.33+0.1x	0.27-0.4x	0.67+0.2x	0.45-0.3x	0.78-2.8x	3.59+2.2x	1.41+0.4x	1.03+0.9x	0.16-0.3x	0.42+0.2x	0.25
FCF Margin	N/A	N/A	N/A	-4672.9%	-3307.0%	-3127.6%	-4121.6%	-1436.0%	-3336.1%	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Return on Equity	-67.2%+59.3pp	-126.5%	N/A	-84.0%+19.0pp	-103.0%+804.5pp	-907.6%	N/A	-59.2%
Return on Assets	-18.8%+34.2pp	-53.0%	N/A	-38.1%-7.0pp	-31.2%+28.6pp	-59.8%	N/A	-33.7%
Current Ratio	1.82+0.2x	1.59-0.7x	2.32+0.6x	1.73+0.4x	1.30+0.4x	0.88-0.8x	1.67-0.6x	2.30
Debt-to-Equity	2.58+1.2x	1.39+0.6x	0.74-0.5x	1.20-1.1x	2.30-11.9x	14.18+12.9x	1.29+0.5x	0.76

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Briacell Therapeutics Corp BCTX

$29.5M

Nextcure NXTC

$35.3M

Biovie Inc BIVI

$8.8M

Carisma Therapeutics Inc CARM

$6.4M

Portage Biotech Inc PRTG

$15.5M

Where Imunon Inc Ranks

Frequently Asked Questions

Is Imunon Inc profitable?

Yes, Imunon Inc (IMNN) reported a net income of $14.5M in fiscal year 2025.

What is Imunon Inc's EBITDA?

Imunon Inc (IMNN) had EBITDA of -$14.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Imunon Inc's return on equity (ROE)?

Imunon Inc (IMNN) has a return on equity of 205.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Imunon Inc's free cash flow?

Imunon Inc (IMNN) recorded an outflow of $14.2M in free cash flow during fiscal year 2025. This represents a 24.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Imunon Inc's operating cash flow?

Imunon Inc (IMNN) recorded an outflow of $13.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Imunon Inc's total assets?

Imunon Inc (IMNN) had $12.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Imunon Inc's capital expenditures?

Imunon Inc (IMNN) invested $281K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Imunon Inc spend on research and development?

Imunon Inc (IMNN) invested $7.8M in research and development during fiscal year 2025.

How many shares does Imunon Inc have outstanding?

Imunon Inc (IMNN) had 3M shares outstanding as of fiscal year 2025.

What is Imunon Inc's current ratio?

Imunon Inc (IMNN) had a current ratio of 2.32 as of fiscal year 2025, which is generally considered healthy.

What is Imunon Inc's debt-to-equity ratio?

Imunon Inc (IMNN) had a debt-to-equity ratio of 0.74 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Imunon Inc's return on assets (ROA)?

Imunon Inc (IMNN) had a return on assets of 118.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Imunon Inc's cash runway?

Based on fiscal year 2025 data, Imunon Inc (IMNN) had $8.8M in cash against an annual operating cash burn of $13.9M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Imunon Inc's Piotroski F-Score?

Imunon Inc (IMNN) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Imunon Inc's earnings high quality?

For every $1 of reported earnings, Imunon Inc (IMNN) used $0.96 of operating cash (-$13.9M OCF vs $14.5M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.